6505--ME/ New Pluvicto Theronastic Therapy Radiopharmaceuticals/STL(VA-26-00053903) 657-26-4-1642-0063

Award Notice Posted

Solicitation number
36C25526N0394
Agency
Awarded
to Novartis Pharmaceuticals Corporation
Set-aside
No set-aside

Opportunity facts

Contract number
36F79720D018036C25526N0394 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs Network Contracting Office 15 awarded a Federal Supply Schedule order to Novartis Pharmaceuticals Corporation on August 5, 2026, for 26 units of PLUVICTO (Lutetium Lu 177 vipivotide tetraxetan) totaling $891,650.76.

The ordering period runs August 5, 2026 through February 5, 2027. Place of performance is VA St. Louis Health Care System John J. Cochran Veterans Hospital, St. Louis, MO. The award was made under unrestricted competition (no set-aside). PLUVICTO is a proprietary radiopharmaceutical indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer who have received prior androgen receptor pathway inhibition and taxane-based chemotherapy. Unit price is $34,294.26. The award is issued under FSS Contract 36F79720D0180, Order Number 36C25526N0394.

Notice text

Ordering Activity / Contracting Office

Department of Veterans Affairs

Network Contracting Office (NCO 15)

3450 S 4th Street Trafficway

Leavenworth, KS 66048

Contract / Order Information

FSS Contract Number: 36F79720D0180

Order Number: 36C25526N0394

Requisition / PO Number: 657-C60305

Effective Date of Award: August 5, 2026Ordering Period: August 5, 2026 through February 5, 2027

Method of Solicitation: FSS order under SF 1449, commercial products and commercial services

Awardee (Contractor)

Novartis Pharmaceuticals Corporation

59 Route 10

East Hanover, NJ 07936

UEI: NG61ZA8TADW3 (as shown on the SF 1449).

Primary Contractor POC:

Yisell Rodriguez, 201 602 5055, yisell.rodriquez@novartis.com.

Place of Delivery / Performance

VA St. Louis Health Care System

John J. Cochran Veterans Hospital

915 North Grand Boulevard

St. Louis, MO 63106

Description of Supplies/Services

This award provides one proprietary radiopharmaceutical agent, PLUVICTO (Lutetium Lu 177 vipivotide tetraxetan), NDC 69488 0010 6, for use by Nuclear Medicine at VA St. Louis Health Care System.

PLUVICTO is indicated for adult patients with PSMA positive metastatic castration resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane based chemotherapy.

The period of performance supports diagnostic and therapeutic use of this radiopharmaceutical in accordance with the Statement of Work included in the SF 1449.

Line Item and Pricing

CLIN 0001: PLUVICTO Lutetium Lu 177 vipivotide tetraxetan, NDC 69488 0010 6.

Quantity: 26 Each.

Unit Price: 34,294.26.

Extended Amount: 891,650.76.

Total Award Amount: 891,650.76.

Funding / Accounting Data

As shown on SF 1449:

657 26 4 1642 0063 / 657 3660 / 160 1642 822900 2580 / 0100L00H6 (Accounting and Appropriation Data).

Invoice and Payment Instructions

Invoices shall be submitted monthly in arrears and must reference PO number 657 C60305 and Order number 36C25526N0394.

All invoices shall be submitted electronically in accordance with VAAR 852.232 72, via the VA Financial Services Center e-invoicing system (Austin, TX).

Payment will be made by: Department of Veterans Affairs Financial Services Center, Austin, TX (see SF 1449 Block 18a and Continuation Page for full details).

Contract Administration / Points of Contact

Contracting Officer:

Michael P. Murphy

Department of Veterans Affairs

Network Contracting Office (NCO 15)

3450 S 4th Street Trafficway, Leavenworth, KS 66048

Email: michael.murphy7@va.gov

Phone: 913 946 1970

Facility Point of Contact (Pluvicto):

Mark Lauridsen

VA St. Louis Health Care System

Email: mark.lauridsen@va.gov

Phone: 314 652 4100 ext. 66522

The Contracting Officer retains sole authority to approve changes or modifications affecting price, quantity, or quality of performance under this contract.

The Contracting Officer s Representative (COR) will be designated separately in accordance with VAAR 852.270 1 and will be responsible for technical and administrative oversight.

Special Terms and Conditions

This order is subject to the terms and conditions of FSS Contract 36F79720D0180 and all clauses incorporated by reference on SF 1449, including VAAR 852.247 71 (Delivery Location), VAAR 852.232 72 (Electronic Submission of Payment Requests), VAAR 852.203 70 (Commercial Advertising), VAAR 852.242 71 (Administrative Contracting Officer), and VAAR 852.246 71 (Rejected Goods).

The VA St. Louis Health Care System s business hours and applicable federal holidays are as set forth in the Statement of Work, and contract performance monitoring will be conducted in accordance with VA quality assurance procedures described therein. Awarded contract 36F79720D018036C25526N0394 to Novartis Pharmaceuticals Corporation for 891650.00 on 2026-08-05.

Files

File Type Posted
36F79720D0180 36C25526N0394_1.docx DOCX document

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors